Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
Status:
Completed
Trial end date:
2020-11-17
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of dasatinib
and Zometa (zoledronic acid) that can be given in combination for the treatment of breast
cancer that has spread to the bone. The safety and effectiveness of this combination will
also be studied.